MichaelJamesBirrerMDPh.D.

Oncology • Little Rock, AR

Professor, Department of Medicine Harvard Medical School Director Gynecologic Medical Oncology

Join to view full profile

Dr. Birrer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Birrer's full profile

Already have an account?

Office
UAMS Medical Center
449 Jack Stephens Drive Winthrop P. Rockefeller Cancer Institute, Second Floor
Little Rock, AR 72205
Phone+1 501-686-8522

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Massachusetts General HospitalResidency, Internal Medicine, 1982 - 1985
Albert Einstein College of MedicineClass of 1982

Certifications & Licensure

VA State Medical License 1900 - Present
AR State Medical License 2019 - 2026
AL State Medical License 2017 - 2019
MA State Medical License 1984 - 2019
MD State Medical License 1985 - 2010
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Boston Magazine Castle Connolly, 2010-2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers Start of enrollment: 2008 Apr 01
Unknown status
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer Start of enrollment: 2009 Dec 01
Completed
Phase 2
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Start of enrollment: 2010 Apr 14
Active, not recruiting
Phase 1, Phase 2
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
PET-CT vs. Integrated MR-PET Scanning of GYN Cancers Start of enrollment: 2013 Mar 01
Unknown status
Early Phase 1
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients Start of enrollment: 2021 Sep 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

41 citations
Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants
Kristin L. White, Joellen M. Schildkraut, Rachel T. Palmieri, Edwin S. Iversen, Andrew Berchuck
Cancer Research. 2012-03-01
57 citations
Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers
Judy N. Quong, Serenella Eppenberger-Castori, Dan H. Moore, Gary K. Scott, Michael J. Birrer
Breast Cancer Research and Treatment. 2002-12-01
532 citations
Inherited Mutations in Women With Ovarian Carcinoma
Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee
JAMA Oncology. 2016-04-01

Journal Articles

Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology
Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)
Alessandro D Santin, Michael Frumovitz, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology
Primordial Germ Cells as a Potential Shared Cell of Origin for Mucinous Cystic Neoplasms of the Pancreas and Mucinous Ovarian Tumors
Leona A Doyle, Daniel W Cramer, Michael Goggins, Ronny Drapkin, Jason L Hornick, Kevin M Elias, Michael Birrer, Michelle S Hirsch, The Journal of Pathology
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
Michael J Birrer, Kathleen N Moore, Clinical Cancer Research
Join now to see all

Other

Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
Michael Birrer, MD, Clinical Cancer Research
https://www.doximity.com/articles/2d76bb27-90e6-4215-9c57-05d1d5652246
UpToDate, Wolters Kluwer Health - 2012-12-20
Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
Michael Birrer, MD, Clinical Cancer Research
https://www.doximity.com/articles/2d76bb27-90e6-4215-9c57-05d1d5652246
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

UAMS College of Medicine Honors Shuk-Mei Ho, Ph.D., as Distinguished Faculty ScholarOctober 24th, 2024
Bispecific Antibody Provides Long-Term Responses in Some Advanced Cervical CancersJuly 31st, 2024
Arkansas to Send Reserve Funds to UAMS for Cancer Center, Redirect Medical Marijuana TaxApril 13th, 2023
Join now to see all

Grant Support

Novel Biomarkers In Ovarian CancerNational Cancer Institute2010–2012
Proteomic, Genetic &Longitudinal Pathways To Ovarian Cancer Biomarker DiscoveryNational Cancer Institute2010–2011
Genomic Stratification Of Ovarian Cancer PatientsNational Cancer Institute2010
The Use Of Transcriptional Factors As Targets And Agents In CarcinogenesisDivision Of Clinical Sciences - Nci2009
The Molecular Genetics Of Gynecologic CancersDivision Of Clinical Sciences - Nci2009
The Use Of Transcriptional Factors As Targets And Agents In CarcinogenesisNational Cancer Institute2007–2008
The Molecular Genetics Of Gynecologic CancersNational Cancer Institute2007–2008
The Use Of Transcriptional Factors As Targets And AgentsDivision Of Clinical Sciences - Nci2002–2006
The Molecular Mechanisms Of Oncogene ActionDivision Of Clinical Sciences - Nci1996–2006
The Molecular Genetics Of Gynecologic CancersDivision Of Clinical Sciences - Nci1996–2006
Transcriptional Factors As Targets And Agents In Carcin.Division Of Clinical Sciences - Nci2004
Use Of Transcriptional Factors As Targets And AgentsDivision Of Clinical Sciences - Nci2001
Molecular Mechanisms Of Oncogene ActionDivision Of Clinical Sciences - Nci2001
Molecular Genetics Of Gynecologic CancersDivision Of Clinical Sciences - Nci2001
The Use Of Transcriptional Factors As Targets And Agents In CarcinogenesisDivision Of Clinical Sciences - Nci1999–2000
Use Of Transcriptional Factors As Targets And Agents In CarcinogenesisDivision Of Clinical Sciences - Nci1997–1998
Transcriptional Factors As Targets And Agents For ChemopreventionDivision Of Clinical Sciences - Nci1996